Pellix .05 mg/mL
calcipotriene · SOLUTION · Perfero Pharma, Inc.
Pellix is a solution containing calcipotriene at .05 mg/mL, taken topical. Manufactured by Perfero Pharma, Inc..
Key Facts
- Brand Name
- Pellix
- Generic Name
- calcipotriene
- NDC Code (Product)
87143-300- Manufacturer
- Perfero Pharma, Inc.
- Strength
- .05 mg/mL
- Dosage Form
- SOLUTION
- Route
- TOPICAL
- Marketing Status
- Application #
- ANDA078468
- Drug Class
- Vitamin D Analog [EPC]
- Marketing Start
- 05/04/2026
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
INDICATIONS AND USAGE Pellix™ (calcipotriene) Topical Solution, 0.005% (Scalp Solution) is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.
Dosage & Administration
DOSAGE AND ADMINISTRATION Comb the hair to remove scaly debris and after suitably parting, apply Pellix™ Topical Solution, 0.005% (Scalp Solution), twice daily, only to the lesions, and rub in gently and completely, taking care to prevent the solution spreading onto the forehead. The safety and efficacy of Pellix™ Topical Solution, 0.005% (Scalp Solution), have been demonstrated in patients treated for eight weeks. Keep Pellix™ Topical Solution, 0.005% (Scalp Solution), well away from the eyes. Avoid application of the solution to uninvolved scalp margins. Always wash hands thoroughly after use.
Warnings
WARNINGS Avoid contact with the eyes or mucous membranes. Discontinue use if a sensitivity reaction occurs or if excessive irritation develops on uninvolved skin areas. Drug product is flammable. Keep away from open flame.
Contraindications
CONTRAINDICATIONS Pellix™ Topical Solution, 0.005% (Scalp Solution), is contraindicated in those patients with acute psoriatic eruptions or a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.
Adverse Reactions
ADVERSE REACTIONS In controlled clinical trials, the most frequent adverse reactions reported to be related to Pellix™ Topical Solution, 0.005% (Scalp Solution), use were transient burning, stinging and tingling, which occurred in approximately 23% of patients. Rash was reported in about 11% of patients. Dry skin, irritation and worsening of psoriasis were reported in 1-5% of patients, Skin atrophy, hyperpigmentation, hypercalcemia, and folliculitis were not observed in these studies, but cannot be excluded. To report SUSPECTED ADVERSE REACTIONS, contact Perfero Pharma, Inc. at 1-973-629-0109 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Frequently Asked Questions
What is Pellix used for?
Pellix contains calcipotriene. It is a solution taken topical. Consult your doctor for specific uses.
Is Pellix a controlled substance?
Pellix is not classified as a controlled substance by the DEA.
What is the generic name for Pellix?
The generic name for Pellix is calcipotriene. There are 11 other brand versions of calcipotriene.
What is the NDC code for Pellix .05 mg/mL?
The NDC (National Drug Code) for Pellix .05 mg/mL is 87143-300, listed by Perfero Pharma, Inc..
Other Calcipotriene Brands
See all →- SORILUX50 ug/g51862-376
- Trionex72835-902
- Calcipotriene and Betamethasone Dipropionate.643 mg/g45802-816
- Calcipotriene and Betamethasone Dipropionate.643 mg/g63629-2520
- Calcipotriene.05 mg/mL0713-0318
- TACLONEX.5 mg/g50222-501
- calcipotriene50 ug/g51862-512
- Calcipotriene and Betamethasone Dipropionate50 mg/g51672-1402
- Calcitrene.05 mg/g51672-5278
- Calcipotriene and Betamethasone Dipropionate.5 mg/g66993-938
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)